« Back
Home /
Ponatinib

Ponatinib

Item no.	HY-12047-10mg
Manufacturer	MedChem Express
CASRN	943319-70-8
Amount	10 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 50 mg 5 mg
Category	Oncology Cardiovascular Research Thrombosis & Hemostasis Inhibitors & Compound Libraries Small Molecules By Organ Heart & Blood Cancer
Type	Inhibitors
Specific against	other
Purity	99.67
Citations	[1]O'Hare T, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell, 2009, 16(5), 401-412.\|[2]Gozgit JM, et al. Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies. Mol Cancer Ther, 2011, 10(6), 1028-1035.\|[3]Uchida T, et al. Hes1 upregulation contributes to the development of FIP1L1-PDGRA-positive leukemia in blast crisis. Exp Hematol. 2014 May;42(5):369-379.e3. Acta Pharm Sin B. 2023 Oct;13(10):4253-4272. Acta Pharmacol Sin. 2021 Jan;42(1):108-114. Biochem Pharmacol. 2021 Oct:192:114710. Biomed Pharmacother. 2024 Nov:180:117569. Biomed Pharmacother. 2025 Jun 20:189:118246. Biomolecules. 2022 Jun 11;12(6):819. bioRxiv. 2024 Apr 21. bioRxiv. 2025 February 26. bioRxiv. 2025 May 5:2025.04.30.651490. bioRxiv. 2025 Sep 30. Blood Vessel Thromb Hemost. 2025 Nov 17. BMC Chem. 2025 Aug 22;19(1):248. Cancer Discov. 2021 Jan;11(1):126-141. Cancer Sci. 2025 Apr;116(4):1115-1125. Cell Rep Med. 2025 Apr 2:102053. Clin Chim Acta. 2018 May:480:180-185. Commun Biol. 2024 Jul 10;7(1):843. Eur J Pharmacol. 2020 Dec 15;889:173292. Exp Hematol. 2014 May;42(5):369-379.e3. Fundam Clin Pharmacol. 2021 Oct;35(5):919-929. Harvard Medical School LINCS LIBRARY Heliyon. 2024 Sep 28;10(19):e38637. Int J Biol Macromol. 2024 Dec 2:138305. J Chem Eng Data. 2024 Jun 10. J Ethnopharmacol. 2023 Jun 12:309:116275. J Ethnopharmacol. 2024 Apr 6:323:117669. J Ethnopharmacol. 2025 Sep 17;355(Pt A):120621. J Hypertens. 2025 May 1;43(5):827-840. J Inflamm Res. 2025 Jun 26:18:8447-8475. J Med Chem. 2019 May 23;62(10):5006-5024. J Med Chem. 2024 Nov 28;67(22):20571-20579. Leuk Res. 2016 Jun:45:24-32. Neurosci Bull. 2020 Mar;36(3):263-276. Pharmaceuticals (Basel). 2022 Aug 29;15(9):1073. Pharmacogn Mag. 2023 Jul 20. PLoS One. 2021 Sep 30;16(9):e0258140. PLoS One. 2022 Feb 14;17(2):e0263822. PLoS One. 2024 Nov 1;19(11):e0308647. Research Square Preprint. 2021 May. Research Square Print. 2023 Mar 23. Sci Rep. 2025 Jul 2;15(1):22961. Sci Rep. 2025 Oct 16;15(1):36227. Sci Transl Med. 2018 Jul 18;10(450):eaaq1093. Target Oncol. 2020 Oct;15(5):659-671. Technical University of Munich. 24.01.2018. University of Pittsburgh. 2025. Biomaterials. 2022 Oct:289:121800.
Smiles	CC1=C(C=C(C=C1)C(NC2=CC(C(F)(F)F)=C(C=C2)CN3CCN(CC3)C)=O)C#CC4=CN=C5N4N=CC=C5
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	AP24534
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Category	Reference compound / Active compounds; API
Manufacturer - Targets	Autophagy; Bcr-Abl; FGFR; PDGFR; Src; VEGFR
Manufacturer - HS Code	H301, H311, H315, H319, H331, H335
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	532.56
Product Description	Ponatinib (AP24534) is an orally active multi-targeted kinase inhibitor with IC50s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively[1].
Manufacturer - Research Area	Cancer
Solubility	DMSO : 25 mg/mL (ultrasonic; warming; heat to 60°C)
Manufacturer - Pathway	Autophagy; Protein Tyrosine Kinase/RTK
Clinical information	Launched
Isoform	PDGFRα; VEGFR2/KDR/Flk-1
UNSPSC Code	12352005
Precautionary	H301, H311, H315, H319, H331, H335

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.